REG - Inspiration Health - Change of Adviser

Inspiration HealthcareAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nRSN2788Aa&default-theme=true

RNS Number : 2788A  Inspiration Healthcare Group PLC  14 April 2026

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Appointment of Nominated Adviser and Joint Broker

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company, is pleased to announce the appointment of Singer Capital Markets as
Nominated Adviser & Joint Broker to the Company with immediate effect.
Singer Capital Markets will work alongside Cavendish Capital Markets, the
Group's existing Joint Broker.

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                                               Tel: +44 (0)330
                                                                175 0000
 Raffi Stepanian, Chief Executive Officer
 Alan Olby, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                                                              Tel: +44 (0)20 3100 2000
 Alex Bond
 Phil Davies
 Jalini Kalaravy

 Cavendish Capital Markets (Joint Broker)                                             Tel: + 44 (0)20 7220 0500
 Giles Balleny / Joe Smith
 Nigel Birks
 Harriet Ward

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
                                   (mailto:inspirationhealthcare@walbrookpr.com)
 Anna Dunphy                                                    Mob: +44 (0) 7876 741 001
 Rachel Broad                                                   Mob: +44 (0) 7747 515 393

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering
medical technology. Based in the UK, the Company specialises in neonatal
intensive care medical devices, which are addressing a critical need to help
to save the lives and improve the outcomes of patients, starting with the very
first breaths of life.

 

The Company has a broad porfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy. In the rest of the world the Company has an
established network of distribution partners around the world giving access to
more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and in the USA from its facility in
Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found at
www.inspirationhealthcaregroup.com (http://www.inspirationhealthcaregroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPVXLFFQZLXBBX



            Copyright 2019 Regulatory News Service, all rights reserved